Skip to main content
Top
Published in: Medical Oncology 1/2014

01-01-2014 | Short Communication

Intact expression status of RASSF1A in acute myeloid leukemia

Authors: Davood Zare-Abdollahi, Shamsi Safari, Abolfazl Movafagh, Mojtaba Ghadiani, Sahand Riazi-Isfahani, Mir Davood Omrani

Published in: Medical Oncology | Issue 1/2014

Login to get access

Abstract

As a typical tumor suppressor gene, transcriptional silencing of ras-association domain family 1, isoform A (RASSF1A) is caused by biallelic methylation or the condition that one allele is methylated and then the other allele lost by allelic loss, as second hit. RASSF1A is inactivated epigenetically and thus down-regulated in many solid tumors. In summary, for the first time, we analyzed the expression status of RASSF1A in a cohort of 56 de novo acute myeloid leukemia (AML) patients using quantitative real-time polymerase chain reaction. Results of our study indicate that patients with AML exhibited no differences in the RASSF1A gene expression comparing to normal controls. In conclusion, expression status of RASSF1A remained intact in our target samples, indicating that RASSF1A expression variation does not participate in the pathogenesis and the progression of AML.
Literature
1.
go back to reference Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.PubMedCrossRef Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.PubMedCrossRef
2.
go back to reference Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.PubMedCrossRef Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.PubMedCrossRef
3.
go back to reference Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–28.PubMed Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–28.PubMed
4.
go back to reference Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748–58.PubMedCrossRef Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748–58.PubMedCrossRef
5.
go back to reference Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253–61.PubMedCrossRef Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253–61.PubMedCrossRef
6.
go back to reference Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802–7.PubMedCrossRef Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802–7.PubMedCrossRef
7.
go back to reference Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557–63.PubMedCrossRef Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557–63.PubMedCrossRef
8.
go back to reference Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437–43.PubMedCrossRef Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437–43.PubMedCrossRef
9.
go back to reference Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.PubMedCrossRef Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.PubMedCrossRef
10.
go back to reference Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509–18.PubMedCrossRef Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509–18.PubMedCrossRef
11.
go back to reference Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345–9.PubMedCrossRef Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345–9.PubMedCrossRef
12.
go back to reference Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994–1002.PubMedCrossRef Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994–1002.PubMedCrossRef
13.
go back to reference Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.PubMedCrossRef Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.PubMedCrossRef
14.
go back to reference Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–55.PubMedCrossRef Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–55.PubMedCrossRef
15.
go back to reference Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.PubMedCrossRef Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.PubMedCrossRef
16.
go back to reference Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491–8.PubMed Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491–8.PubMed
17.
go back to reference Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245–52.PubMedCrossRef Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245–52.PubMedCrossRef
18.
go back to reference Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–86.PubMedCrossRef Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–86.PubMedCrossRef
19.
go back to reference Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–5.PubMedCrossRef Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–5.PubMedCrossRef
20.
go back to reference Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130–2.PubMedCrossRef Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130–2.PubMedCrossRef
21.
go back to reference Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232–42.PubMedCrossRef Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232–42.PubMedCrossRef
22.
go back to reference Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581–609.PubMedCrossRef Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581–609.PubMedCrossRef
23.
go back to reference Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103–7.PubMedCrossRef Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103–7.PubMedCrossRef
Metadata
Title
Intact expression status of RASSF1A in acute myeloid leukemia
Authors
Davood Zare-Abdollahi
Shamsi Safari
Abolfazl Movafagh
Mojtaba Ghadiani
Sahand Riazi-Isfahani
Mir Davood Omrani
Publication date
01-01-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0770-x

Other articles of this Issue 1/2014

Medical Oncology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine